10 February 2016

Grant of Share Options

VERONA PHARMA PLC - Grant of Share Options

Read more

21 January 2016

Director Dealing

Verona Pharma plc

Read more

11 January 2016

Directorate Change

VERONA PHARMA PLC - Directorate Change

Read more

3 December 2015

Director Dealing

VERONA PHARMA PLC - Director Dealing

Read more

1 December 2015

Holding(s) in Company

 

Read more

11 November 2015

RPL554 paper published in American Journal of Physiology

VERONA PHARMA PLC - RPL554 paper published in American Journal of Physiology

Read more

5 November 2015

Patient enrolment completed in RPL554 PhIIa studies

VERONA PHARMA PLC - Patient enrolment completed in RPL554 PhIIa studies

Read more

14 October 2015

Start of RPL554 Phase IIa combination study

VERONA PHARMA PLC - Start of RPL554 Phase IIa combination study

Read more

8 October 2015

RPL554 data presented at North American CF Conference

VERONA PHARMA PLC - RPL554 data presented at North American CF Conference

Read more

29 September 2015

Positive headline data from RPL554 study

VERONA PHARMA PLC - Positive headline data from RPL554 study

Read more

Targeting unmet needs

384m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients

Read more about COPD and CF in the unmet needs section of this website

Go

Basic & Clinical Pharmacology & Toxicology

Peer-reviewed publication on dual PDE3/4 inhibitors as novel treatments for COPD

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us